sorafenib has been researched along with Solitary Fibrous Tumors in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bompas, E; Chaigneau, L; Chevreau, C; Fournier, C; Isambert, N; Penel, N; Valentin, T | 1 |
| Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
| Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC | 1 |
| Bihan, H; Cohen, R; Coindre, JM; Des Guetz, G; Le Jeune, S; Mourad, JJ | 1 |
2 trial(s) available for sorafenib and Solitary Fibrous Tumors
| Article | Year |
|---|---|
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Solitary Fibrous Tumors; Sorafenib; Treatment Outcome | 2013 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
2 other study(ies) available for sorafenib and Solitary Fibrous Tumors
| Article | Year |
|---|---|
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2010 |
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Solitary Fibrous Tumors; Sorafenib | 2013 |